Top Stories News

BioLineRx announced yesterday its worldwide, exclusive license agreement with Ramot at Tel Aviv University for a neuropathic and inflammatory pain treatment.

Austria's F-Starfor announced yesterday the agreement with Merck Serono for the discovery of new antibody-derived therapeutics against inflammatory disease targets.

Evotec and Roche have teamed up to develop and commercialize MAO-B inhibitor of Evotec for the patients with Alzheimer's disease.

The WHO and the FIP signed a joint statement seeking to involve pharmacists in tuberculosis care and control.

Merck originally licensed the rights to the programme in 2007 in a deal potentially worth as much as $170.5m.

Pfizer has granted Sanofi a licence to manufacture a generic version of the product and launch it after Lipitor's patent expires in the country on 7 May 2012.

Oxford Pharmascience partners with University of London to have the option to license and research an advanced colonic drug delivery technology.

According to trial results announced recently, Crestor, the statin drug from AstraZeneca, failed to best Lipitor at clearing clogged arteries.

The new research site will be Pfizer’s Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units.

Pfizer, the world’s largest drugmaker, settles a lawsuit with the Indian generic-drug maker Dr. Reddy’s Laboratories over the cholesterol treatment Lipitor.

Teva has signed an agreement with Sinclair IS to gain exclusive commercialisation rights of oncology medication Episil in Germany, Spain, Poland, Switzerland and the Czech Republic.

Bayer HealthCare's affiliate, MEDRAD, Inc. acquires Pathway Medical Technologies to strengthen its MEDRAD Interventional business by expanding its presence in the field of vascular intervention technologies.

Biopharmaceutical firm OXiGENE, Inc. decides to restructure in an to focus resources on its most promising early-stage clinical programs.

Pfizer's subsidiary, Eclipse Acquisition Corp. , has extended the expiration date of its tender offer for Icagen.

Under the agreement, ICON will become a preferred provider for full-service clinical pharmacology and exploratory clinical studies.

Valeant Pharmaceuticals will acquire cold and flu medicine maker Afexa Life Sciences for approximately $76 million.

The study of 549 hospitals indicates that 52% of respondents purchased one or more pharmaceutical products from back-door suppliers during the past two years.

Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales.

Under terms of the deal, Zymeworks will receive an up-front fee and could earn research, development, and regulatory milestones of up to $187 million.

India's Piramal plans to invest at least $1.5 billion in biotech acquisitions and Big Pharma joint ventures to expand its overseas business.

Eisai will establish its Canadian headquarters in Mississauga, Ontario and the expansion into Ontario will increase access to a variety of therapies and medications.

British health authorities warned that packages of an over-the-counter painkiller were found to contain antipsychotic drugs.

Two UK firms have agreed to collaborate on drug discovery.

The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, “CPHI-Online” had an interview with Ms. Yu Lingmin, Manager of NO.1 Pharmaceutical Dept, A.H.A Internatio...

Sanofi announced to acquire India's nutraceuticals company Universal Medicare. The transaction is expected to close in the fourth quarter of this year.

The combination of two research organisations will enable them to offer integrated pharmaceutical and clinical development solutions.

The HHS has announced the award of $137 million of grants to states to fund prevention and health improvement services and programs.

Indian Clinigene International Ltd. and U.S. Spaulding Clinical Research will cooperate to develop their clinical pharmacology services.

Catalent Pharma Solutions announced that it will buy the clinical trial supplies business of Aptuit LLC for $410 million.

The two companies will reconfigure their assets and personnel to maximize design and engineering operations and build out their manufacturing facilities.

The certificate states that WuXi's BAS facility in Shanghai is able to carry out ADME, toxicokinetic and pharmacokinetic studies, and hERG assay and biomarker studies with respect to OECD and EU GLP principles.

The collaboration will combine Bend’s formulation/processing expertise for delivering poorly soluble compounds with Xcelience’s early-phase development expertise.

Par Pharmaceutical Companies said it has agreed to acquire privately-held Anchen Pharmaceuticals for $410 million in cash.

The study found that of 192 pharmaceutical adverts, only 18% were compliant with the US FDA guidelines.

With the new premises, Novo Nordisk will be consolidating a number of administrative functions currently scattered across Greater Copenhagen.

A study estimates that needle-free drug delivery methods will have annual revenue growth of 15.1% on average from 2011 to 2016 to reach US$6.2bn.

Takeda will have a JPY23.9bn (US$312m) government subsidy to develop a new influenza vaccine.

The two pharma firms have added the development and commercialization of additional strengths of generic Focalin XR for the U.S. market to their existing agreement.

Boehringer Ingelheim will apply ProBioGen's technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.

Paladin Labs will purchase drug technology developer Labopharm in a deal valued at over $20.4 million.

Roche's Toclizumab is already licensed to treat adults with severe arthritis, but as of today the drug will be available for children.

According to the survey, changes in healthcare legislation and reform top the list of business concerns of healthcare companies in the US and Asia.

Carlyle Group is in exclusive talks to buy North Carolina-based CRO company Pharmaceutical Product Development.

Swiss firm 4-Antibody inked a collaboration agreement with Human Genome Sciences for the discovery and development of fully human antibodies.

The acquisition expands GE Healthcare’s offering of products and services for cell biology research and the discovery and manufacture of biopharmaceuticals.

The company has paid $175,000 to four families in the first of a series of payments as part of an out-of-court settlement reached in 2009.

Bayer HealthCare will support WHO and the Stop TB Partnership in the fight against multidrug-resistant tuberculosis by making 620,000 tablets of the antibiotic moxifloxacin available to WHO.

Pfizer has partnered with the University of California's San Diego Health Sciences in a drug discovery collaboration.

According to a new report focused on M&A activity, 18 biotech companies were sold during the first half of this year for total upfront values of $51.6 billion.

The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, “CPHI-Online” had an interview with Mr. Zhou Jianmin, Board Member /Deputy General Manager of Liaocheng W...

The approval follows the results from two Phase III trials assessing the safety and efficacy of BDP Nasal HFA in the treatment of SAR and PAR.

The project will focus on developing treatments across three technological platforms.

GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models to identify key molecular mechanisms.

The acquisition covers K-V Pharma's certain packaging, manufacturing and laboratory facilities, as well as equipment specific to the generic business.

Ipca said its UK subsidiary has acquired Onyx Research Chemicals, the holding company of Onyx Scientific Ltd, a contract manufacturing organisation.

Unigene will receive up to approximately $2.2 million in milestone payments from GSK to undertake certain development and manufacturing activities.

The UK's healthcare regulators have recommended against the prescription of Novartis' multiple sclerosis drug Gilenya to NHS patients due to uncertainties over its clinical effectiveness.

From a public health perspective, an ideal influenza vaccine would protect against multiple strains of the virus, regardless of their hemagglutinin structure.

The partnership will leverage the strengths of both companies and facilitate collaboration on integrated clinical services to engage pharmaceutical clients who demand a global footprint.

Under the agreement, MolMed will develop a production process for an investigational gene therapy for ADA-SCID, a very rare disease that affects approximately 350 children worldwide.

The number of drug approvals is set to increase further, with more than a dozen drug candidates still scheduled for review before the end of the year.

Pfizer hopes to sell an over-the-counter version of its best-selling drug Lipitor when its generic forms are available in November.

Vectura Group has inked a new US partnership deal for its generic lung drug VR315.

Under the terms of the agreement, Merck will receive specific rights to market PCV in certain designated territories and Serum will receive specific rights in other territories.

Celgene and Acceleron will jointly develop, manufacture and commercialize ACE-536, a novel protein therapeutic for the treatment of anemia.

Swiss drugmaker Novartis racked up 17 new drug approvals from 2000 to 2010. But over the past 60 years, the company has accounted for only 16.

Capsugel will maintain a corporate presence in the US. All Pfizer employees currently dedicated to this business will be transferred to Capsugel.

The pilot programs are part of the FDA's global strategy to ensure the safety and quality of imported products.

The New York-based pharma company has reported its second quarter financial results.

Merck is planning global submissions for ridaforolimus in Europe, the U.S., Canada, Asia-Pacific and Latin America and other key markets.

A new study says more than half the people who take opioids for chronic pain are likely to still be taking the painkillers five years later.

As part of the next phase of its restructuring programme, Merck expects to reduce its workforce by an additional 12 to 13% by the end of 2015.

The settlement will ensure that none of the 27 members of the economic and trading bloc will detain 'Made in India' consignments of generic medicines, which are transiting through EU ports.

Total first half sales in North America were EUR 4,393 million, an increase of 5.1 percent compared with first-half 2010 sales.

Russia's $1.3 billion federal program for the development of the pharmaceutical industry will help to persuade companies to buy APIs in Russia instead of India or China.

According to the World Health Organization, the world's seasonal flu vaccine production capacity will double by 2015.

Under the partnership, INC Research agrees to work with Debiopharm on future clinical studies.

GlaxoSmithKline reports its financial results for the second quarter ended June 30, 2011.

The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, “CPHI-Online” had an interview with Mr. Chen Yuming, General Manager of Chengdu GELAIPU SCI & TECH, CO., ...

The EMA has agreed to a recall of Vimpat 15 mg/ml syrup because of a quality defect in some batches.

Lonza is in partnership with Genesis Biopharma to develop Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

At the time of the Hong Kong recall, GSK and health officials there emphasized that the amounts of plasticizer found weren't likely to cause harm to humans if they were taken at the proper doses.

Roche will deliver diagnostics to support the largest infant testing initiative in the world that aims to identify HIV-infected children during the first months of life.

Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals in an all-cash transaction worth up to $475 million.

The EMA said Takeda Pharmaceutical's diabetes pill Actos should carry new warnings about its possible link to bladder cancer.

The EMA has introduced some changes on package to contribute towards the safe and effective use of medicines.

One lot of calcium gluconate injections distributed by American Regent has been recalled due to silicone particle contamination.

Pfizer Inc. said Wednesday it will acquire the remaining stake in Icagen Inc.

Merck and Roche have expanded their recent collaboration to jointly promote hepatitis C treatment Victrelis.

The drug discovery outsourcing market has grown significantly over the past two decades and will be worth US$16.21bn by 2015.

DNDi will work with partners to create an affordable therapy for children suffering from HIV/AIDS.

InterMed Discovery will make its natural product screening libraries available and provide follow-on services to BioFocus.

Pfizer stated its decision to withdraw was based on the CHMP’s view that the data provided so far does not allow the Committee to conclude on a positive benefit-risk balance in the applied for indication.

South Africa has decided to take HIV drug pricing into its own hands by setting up its own drug company to help provide such medicines.

Roche plans to submit the study results of pertuzumab for global regulatory approval this year.

The FDA has approved the influenza vaccine formulation for the 2011-2012 vaccine. Six manufacturers are licensed to produce and distribute influenza vaccine for the United States during the upcoming season.

The Court's injunction extends until November 2013, after which Teva may sell Neutroval in the US.

The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, “CPHI-Online” had an interview with Ms. Jiang Hua, the assistant president of Luye Pharma Group.

The deal was Valeant's second planned dermatology acquisition announced in the past week.

According to a survey by audit, tax and advisory firm KPMG, US pharmaceutical firms will be on the acquisition hunt over the next two years.

The outsourcing company Icon has acquired technology firm Firecrest Clinical to enhance site performance.

Singapore-based Aslan Pharmaceuticals and Array BioPharma have signed a license agreement to develop Array’s cancer drug called ARRY-543.

Particle Sciences and Absorption Systems have formed a partnership to provide clients with enhanced drug development services.

EMA will improve the search and data-output of its databases, supplying pharmaceutical manufacturers with tools on the ‘detection and analysis of signals on adverse reactions’ by 2015.

Under the terms of the agreement, Eisai shall acquire from Orion the exclusive rights to market the two products in China, and will distribute them through its Chinese subsidiary Eisai China Inc.

The projects will be open for scientists from universities, research institutions and private companies in India and Denmark conducting research within the health science biotechnology area.

The Medicines Patent Pool enables drug manufacturers to produce cheaper, generic versions of drugs currently under patents for use in developing or poorer countries.

For the first time in almost 50 years Canadians living with lupus have a new treatment option.

Under the terms of the agreement, Micromet will be primarily responsible for the discovery and preclinical development of the BiTE antibodies. Amgen will lead the clinical development, manufacturing, and commercialization of any products resulting from...

Valeant Pharmaceuticals International will acquire Dermik, a dermatology unit of Sanofi in the U.S. and Canada, for approximately $425 million.

The European Medicines Agency is reviewing the cardiovascular risk of the anti-arrhythmic medicine Multaq.

Teva has reached a compromise with Merck and will not sell cholesterol drugs Vytorin and Zetia until 2017.

Novo Nordisk and the advocacy organization Children with Diabetes, Inc will develop and distribute resources to help newly diagnosed children with type 1 diabetes adjust to their new lifestyle.

Bristol-Myers Squibb is the only company that has registered the drug Amphotericin B in South Africa to treat the AIDS defining-disease cryptococcal meningitis.

During the first quarter of 2011, Indian pharma companies filed 90 DMFs as compared to 75 and 91 DMFs respectively during first quarter of 2010 and 2009.

Biogen Idec has selected Unilabs to provide a companion diagnostic anti-JCV antibody assay test.

Malaysian Biotechnology Corporation is boosting Malaysia’s biotechnology industry through a series of agreements and collaborations.

Under the terms of the agreement, Bristol-Myers Squibb will fund the development of IPH2102, make an upfront payment of $35 million and additional payments of up to $430 million.

A new report says the growing prevalence of type 1 and type 2 diabetes is ensuring rapid growth for insulin management systems.

The FDA inspections in the last few weeks are raising hopes among some of Indian companies they will shortly be able to export medicines to the world’s largest drug market.